Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05972694
Other study ID # STUDY20230070
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date July 2, 2024
Est. completion date November 2, 2025

Study information

Verified date May 2024
Source Case Western Reserve University
Contact Abigail Basson, PhD
Phone 2163276003
Email abigail.basson@uhhospitals.org
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The overall objective of this pilot intervention study is to determine the impact of grape powder (46g/day freeze dried whole grape powder provided by the California Table Grape Commission) on the gut microbiotacomposition in adult patients with the IBD subtype Crohn's disease (CD).


Description:

This protocol is designed to investigate the effect of grape powder consumption in Inflammatory Bowel Disease (IBD), in particular how grape powder consumption (provided as 46g/day grape powder; equivalent to 1.5 cups fresh grapes) alters the gut microbiota (GM) composition in humans with IBD. The investigators will focus on studying IBD patients affected with CD as a proof of principle that could be tested later in other IBD subtype (ulcerative colitis or others specific surgical conditions). The overall objective of this pilot intervention study is to determine the impact of grape powder (46g/day freeze dried whole grape powder provided by the California Table Grape Commission) on the GM composition in adult patients with the IBD subtype Crohn's disease (CD). An 28 day pilot study in adult CD patients at the Digestive Health Institutes (DHI) of University Hospitals Cleveland Medical Center (UHCMC). table Participation in this study will last for a maximum of 28 days and will consist of two phases. Phase I (baseline period - 7 days) where all grapes and berries will be removed from the diet, and Phase II (intervention period - 21 days) where participants will be supplemented with 46g/d freeze-dried grape powder consumed as 22.5g packets twice daily. The dose of 46g/day of grape powder is equivalent to 1.5 cups of grapes. Participants will be asked to avoid consumption of all other grapes/berries during phase II. The investigators will compare the before and after changes in gut microbiota composition.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 20
Est. completion date November 2, 2025
Est. primary completion date September 2, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Documented diagnosis of Crohns disease. CD outpatients in remission - Harvey Bradshaw-index in remission (<6 score) - Capable of providing consent to participate. - Able to complete daily surveys and take oral nutrition - Able to record daily meal intake Exclusion Criteria: - Short bowel syndrome. - Hospitalized patients. - Individuals who lack consent capacity, including the mentally ill, prisoners, cognitively impaired participants, dementia patients. - Known drug abuse. - Known parasitic disease of the digestive system. - Symptomatic intestinal stricture. - Presence of an ostomy. - Other conditions that would be a contraindication to consumption of the study diets or preclude the participant from completing the study. - Well-founded doubt about the patients cooperation. - Existing pregnancy or lactation. - History of <1 natural bowel movements per day. - Unable to access to technology that permits the daily completion of study related activities. - Change in IBD medication within past 4 weeks. - Body mass Index <16 kg/m or =35. - Documented C.difficile colitis within four weeks of screening. - Known berry or grape allergy - No probiotic or antibiotic use for the previous 14 days

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Freeze dried grape powder
46g/d freeze-dried grape powder

Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
Case Western Reserve University California Table Grape Commission

Outcome

Type Measure Description Time frame Safety issue
Primary fecal microbiota composition 16S microbiome baseline (pre-intervention), immediately after the intervention
Secondary fecal myleoperoxidase (MPO) fecal marker of inflammation baseline (pre-intervention), immediately after the intervention
Secondary fecal calprotectin fecal marker of inflammation baseline (pre-intervention), immediately after the intervention
Secondary C-reactive protein (CRP) blood marker of inflammation baseline (pre-intervention), immediately after the intervention
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04046913 - The ADDapt Diet in Reducing Crohn's Disease Inflammation N/A
Recruiting NCT05169593 - Prevention of Postoperative Endoscopic Recurrence With Endoscopy-driven Versus Systematic Biological Therapy Phase 4
Recruiting NCT06116604 - Early Bowel Resection for Terminal Ileal Crohn's Disease
Recruiting NCT05316584 - A Novel Remote Patient and Medication Monitoring Solution to Improve Adherence and PerSiStence With IBD Therapy N/A
Recruiting NCT05627128 - A Culturally Tailored Dietary Intervention to Treat Crohn's Disease N/A
Recruiting NCT05294107 - Intestinal Organoids N/A
Withdrawn NCT04349449 - ENTYVIO in Bio-naive Patients With Moderate/Severe Crohn's Disease (CD) in Daily Practice
Completed NCT05051943 - A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
Completed NCT03058679 - Trial of Specific Carbohydrate and Mediterranean Diets to Induce Remission of Crohn's Disease N/A
Completed NCT02871635 - BI 695501 Versus Humira in Patients With Active Crohn's Disease: a Trial Comparing Efficacy, Endoscopic Improvement, Safety, and Immunogenicity Phase 3
Recruiting NCT04266600 - Extended Mesenteric Excision in Ileocolic Resections for Crohn's Disease N/A
Recruiting NCT04539665 - Extended Mesenteric Excision in Ileocolic Resections for Crohn's Disease. N/A
Recruiting NCT03913572 - Treatment of Perianal Disease Using Adipose-derived Stem Cells
Completed NCT03606499 - Real-world Effectiveness of Ustekinumab in Participants Suffering From Inflammatory Bowel Disease (Crohn's Disease or Ulcerative Colitis) With Extra-intestinal Manifestations or Immune-mediated Inflammatory Diseases
Completed NCT03668249 - A Study to Characterize Multidimensional Model to Predict the Course of Crohn's Disease (CD)
Terminated NCT04102111 - A Study Evaluating Participants With Moderately to Severely Active Crohn's Disease Phase 2
Recruiting NCT04997733 - Fecal Microbiota Transplantation in Crohn's Disease as Relay After Anti-TNF Withdrawal Phase 3
Recruiting NCT05906576 - Post-marketing Registry Study of Infliximab for Injection in Chinese Pediatric Crohn's Disease Patients Phase 4
Not yet recruiting NCT04502303 - 18F-FDG and 68Ga-FAPI PET/CT in Crohn's Disease Phase 2
Not yet recruiting NCT04398836 - Preoperative Nutrition for Crohn's Disease Patients Phase 3